XOMA.P Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.60 |
| 52 Week High | US$26.48 |
| 52 Week Low | US$21.40 |
| Beta | 0.93 |
| 11 Month Change | 1.09% |
| 3 Month Change | 2.44% |
| 1 Year Change | 3.94% |
| 33 Year Change | -1.89% |
| 5 Year Change | n/a |
| Change since IPO | 4.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| XOMA.P | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.1% | -0.5% | -1.6% |
| 1Y | 3.9% | 14.9% | 19.8% |
Return vs Industry: XOMA.P underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: XOMA.P underperformed the US Market which returned 19.8% over the past year.
Price Volatility
| XOMA.P volatility | |
|---|---|
| XOMA.P Average Weekly Movement | 1.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: XOMA.P has not had significant price volatility in the past 3 months.
Volatility Over Time: XOMA.P's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| XOMA.P fundamental statistics | |
|---|---|
| Market cap | US$336.12m |
| Earnings (TTM) | -US$45.08m |
| Revenue (TTM) | US$5.81m |
56.5x
P/S Ratio-7.3x
P/E RatioIs XOMA.P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XOMA.P income statement (TTM) | |
|---|---|
| Revenue | US$5.81m |
| Cost of Revenue | US$122.00k |
| Gross Profit | US$5.69m |
| Other Expenses | US$50.77m |
| Earnings | -US$45.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.87 |
| Gross Margin | 97.90% |
| Net Profit Margin | -775.86% |
| Debt/Equity Ratio | 146.6% |
How did XOMA.P perform over the long term?
See historical performance and comparison